Related Experiment Video

Updated: Jun 24, 2025

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
06:15

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Published on: October 27, 2014

27.4K

Brigatinib in ALK-Positive ALCL after Failure of Brentuximab Vedotin

Layla Veleanu1, Laurence Lamant2, David Sibon3

  • 1Institut Necker Enfants Malades, Paris, France.

The New England Journal of Medicine
|June 12, 2024
PubMed
Abstract

No abstract available in PubMed .

More Related Videos

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
04:04

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Published on: February 12, 2017

10.5K
Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography
09:34

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Published on: February 17, 2022

3.3K

Related Experiment Videos

Last Updated: Jun 24, 2025

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
06:15

Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma

Published on: October 27, 2014

27.4K
Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
04:04

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Published on: February 12, 2017

10.5K
Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography
09:34

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Published on: February 17, 2022

3.3K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.5K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K

Articles linked to this work by shared authors, journal, and citation graph.

STAG2 mutations fine-tune the ALK-driven oncogenic program in ALK-positive anaplastic large cell lymphoma.

Blood·2026

Recurrent TNC::PDGFD Fusions in Ossifying Plexiform Tumors of the Skin.

Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc·2026

A PRKCA-Fused Blue Melanocytoma Expressing a Truncated ALK Isoform.

Journal of cutaneous pathology·2026

CircZBTB46, a promising therapeutic target in crizotinib resistant ALK-positive T lymphomas.

Leukemia·2026

CircRNAs derived from the tyrosine phosphatase PTPN22 impact chemosensitivity in ALK-positive T-cell lymphomas.

Scientific reports·2026

Prognostic classification of skin adnexal carcinomas: Results from a prospective study of 980 patients in the French CARADERM network.

European journal of cancer (Oxford, England : 1990)·2026

Helicobacter pylori Infection - Advances, Challenges, and the Road Ahead.

The New England journal of medicine·2026

Ianalumab for the Treatment of Patients with Sjögren's Disease.

The New England journal of medicine·2026

Retatrutide Once Weekly for Treatment of Obstructive Sleep Apnea.

The New England journal of medicine·2026

Perianal fistulizing Crohn's disease increases infliximab clearance and causes low infliximab exposure (ATLANTIC).

Journal of Crohn's & colitis·2026

Long-term efficacy and safety for the complement factor B inhibitor iptacopan in IgA nephropathy.

Kidney international·2026

Correction: Macrophage polarization in acute myocardial infarction: multidimensional regulation and emerging therapeutic opportunitiesa.

Frontiers in immunology·2026

Comparative Effectiveness of Vedolizumab and Ustekinumab in Biologic-Experienced Ulcerative Colitis: A Real-World Multicenter Study from the Güntürk Group.

The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology·2026

Inverse Vaccine Nanomimics: In situ Antigen-Specific Immune Tolerance Induction for Durable Cardiac Repair Post-Myocardial Infarction.

Research (Washington, D.C.)·2026

Biologic and small-molecule therapies for inflammatory bowel disease: mechanisms, comparative evidence and the emerging pipeline.

Frontiers in pharmacology·2026
See all related articles
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies
Jove
Visualize
Contact Us